menu
James E. Kendrick, MD
James E. Kendrick , MD
Obstetrician-gynecologist
Cancer
Overview
Dr. James E Kendrick, MD, FACOG is board certified in gynecology oncologist in Orlando. Dr. Kendrick joined the Gynecologic Oncology Program at the Florida Hospital Cancer Institute in July of 2009. He graduated with honors from the University of Alabama School of Medicine. Dr. Kendrick then completed a four year residency in obstetrics and gynecology followed by a three year fellowship in gynecologic oncology at The University of Alabama at Birmingham. Dr. Kendrick is widely published in numerous academic journals, and currently serves as the principal investigator for all Gynecologic Oncology Group clinical trials available to our patients. His clinical interests include robotic surgery and the surgical and medical management of all gynecologic malignancies.
Articles
Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2024
Clinical outcomes analysis of neoadjuvant chemotherapy for locally advanced vulvar cancer
Gynecologic oncology
2023
Analysis of "sandwich" chemo-radiation therapy for stage IIIC endometrial cancer
Gynecologic oncology
2023
Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancer
Gynecologic oncology
2023
Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer The Nonrandomized Phase 2 VIRO-15 Clinical Trial
JAMA ONCOLOGY
2023
Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
Gynecologic oncology
2022
MALIGNANT PERITONEAL CYTOLOGIC CONTAMINATION WITH ROBOTIC HYSTERECTOMY FOR ENDOMETRIAL CANCER
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
CLINICAL CANCER RESEARCH
2022
Search for Lepton-Flavor Violation in Z-Boson Decays with tau Leptons with the ATLAS Detector
PHYSICAL REVIEW LETTERS
2021
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer
Gynecologic oncology
2021
Education & Training
Education
University of Alabama School of Medicine, Birmingham, AL
Residency
University of Alabama at Birmingham, AL
Fellowship
University of Alabama at Birmingham, AL
Specialty
Gynecology Oncology
Board Certifications
American Board of Obstetrics & Gynecology